The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 25, 2025
Filed:
Apr. 19, 2022
Applicant:
Universite DE Montreal, Montréal, CA;
Inventors:
Pierre Louis Beaulieu, Rosemère, CA;
Eric Beaulieu, Mercier, CA;
Joanne Tan, San Mateo, CA (US);
Yannick Rose, Montréal, CA;
Michael Dore, Saint-Bruno-de-Montarville, CA;
Doris Schuetz, Montréal, CA;
Mukund Ghavre, Saint-Laurent, CA;
Jacques Banville, Saint-Hubert, CA;
Assignee:
Universite de Montreal, Montreal, CA;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 471/04 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 31/541 (2006.01); A61K 31/675 (2006.01); A61P 35/00 (2006.01); C07D 519/00 (2006.01); C07F 9/6561 (2006.01);
U.S. Cl.
CPC ...
C07D 471/04 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/541 (2013.01); A61K 31/675 (2013.01); A61P 35/00 (2018.01); C07D 519/00 (2013.01); C07F 9/6561 (2013.01);
Abstract
Compounds, compositions and their use in the treatment of a proliferative disease or condition such as a said proliferative disease or disorder is associated with a RAF gene mutation and/or a RAS gene mutation. The compounds disclosed are of Formula I or a pharmaceutically acceptable salt or solvate thereof, wherein R, R, R, X, X, Xand Xare as defined herein.